Salute e Benessere

Novo Nordisk A/S - share repurchase programme

Bagsværd , Denmark, 31July 2023– On 9 May 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 30 billion to be executed during a 12-month period beginning 1 February 2023. Under...

European Commission approval of Ztalmy® (ganaxolone) for the adjunctive…

ORION CORPORATIONPRESS RELEASE31 July 2023 at 14.00 EEST European Commission approval of Ztalmy® (ganaxolone) for the adjunctive treatment of epileptic seizures associated with CDKL5 deficiency disorder The European Commission has granted marketing authorisation in the European Union (EU) for Ztalmy ®(ganaxolone) oral suspension for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients...

Evaxion presents promising results on EVX-B1, an AI-designed vaccine against…

EVX-B1, a vaccine againstStaphylococcus aureus (S. aureus)containing AI-identified antigens, is highly protective againstS. aureusdisease in preclinical animal models EVX-B1 immunization resulted in complete bacterial clearance ofS. aureusin multiple organs COPENHAGEN, Denmark, July31, 2023(GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the discovery and development of AI-powered...

Oncolytics Biotech® Announces US$15 Million Bought Deal Offering of Units

Each Equity Unit will consist of one common share of the Company (a "Common Share") and one Common Share purchase warrant (each whole purchase warrant, a "Warrant"). Each Warrant will entitle the holder thereof to purchase one Common Share at an exercise price of US$2.81 (the "Exercise Price") at any time up to 60 months following the Closing (as defined below). Each Equity Unit will consist of one common share of the Company (a " Common Share ") and one…

Nexstim Receives Order for NBS System 5 from Boston VA Hospital

Press release, Helsinki, 31July 2023 at 1 PM(EEST) Nexstim Receives Order for NBS System 5 from Boston VA Hospital Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for a new NBS 5+ including NexSpeech®, to the Boston VA Medical Center.Nexstim's NBS (Navigated Brain Stimulation) System 5 is indicated for the non-invasive, presurgical mapping of motor cortices prior to neurosurgery. With the addition of the NexSpeech® module, speech cortices can also…

Urothelial Carcinoma Market is Expected to Showcase a Significant Growth by…

Key Takeaways from the Urothelial Carcinoma Market Report Key Takeaways from the Urothelial Carcinoma Market Report Discover which therapies are expected to grab the major urothelial carcinoma market share @Urothelial Carcinoma Market Report Urothelial Carcinoma Overview Urothelial carcinoma, also known as transitional cell carcinoma, is a type of cancer that begins in the urothelial cells lining the urinary system, including the bladder, ureters, and urethra. It is the most...

Alvotech Completes $100 Million Convertible Bond Private Placement

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the completion of a private placement, in an overseas directed offering directed solely into Iceland to professional clients or eligible counterparties, of subordinated convertible bonds denominated in Icelandic krona (ISK) and US dollar (the “Bonds”) for a par value of $100 million. Alvotech expects to use the proceeds for continued...

New number of shares and votes in IBT

The number of shares and votes in Infant Bacterial Therapeutics AB (publ) has changed due to the recently completed rights issue (for further information, see the company's press release on 4 July 2023). Through the rights issue, the number of shares in IBT increased with 2,245,236 (of which 75,547 class A shares and 2,169,689 class B shares) and the number of votes increased with 2,925,159. Today, on the last trading day of the month, there are in total 13,471,420 shares (of which 453,283...

Yodaplus: Shaping the Future of Industries with Powerful AI Integration

With its wide range of services and deep industry knowledge, Yodaplus has been a game changer – enabling organizations to focus on their core operations and achieve sustainable growth. And now, by integrating AI into services, Yodaplus helps businesses navigate the complex digital transformation landscape more efficiently, creating a competitive edge. With its wide range of services and deep industry knowledge, Yodaplus has been a game changer – enabling organizations to focus on their core...

OKYO Pharma Limited Announces Withdrawal of Public Offering

LONDON and NEW YORK, July31, 2023(GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announced the withdrawal of its proposed public offering of ordinary shares. The decision was made in response to changing market conditions and the Company's commitment to prioritizing...

Groupe Casino: Revolving Credit Facility Waiver Erratum

Revolving Credit Facility Waiver***Erratum*** Paris, 31 July 2023Further to its press release published on 28 July 2023, the Group clarifies that it has obtained a waiver from the lenders under the revolving credit facility (RCF) to declare any early repayment based on events of default resulting directly from non-compliance with the financial covenants at 30 June 2023 (and not at 30 September 2023, as announced on 28 July 2023). It should be noted that the request made by the...

Mithra and Searchlight Pharma Announce Donesta® Licensing Agreement for Canada

Mithraand Searchlight Pharma Announce Donesta ® Licensing Agreement for Canada Mithra to receive up to€ 17.05 million in licensing fees and regulatory and sales milestones, along with tiered royalties on annual net salesPromising topline safety results from the Donesta® Phase 3 trial in North AmericaSearchlight Pharma anticipates filing of Canadian regulatory submission in H1 2024 Liege, Belgium and Montreal,...

J INTS BIO, Novel Oral 4th Generation EGFR TKI 'JIN-A02' - Dosing of First…

This global phase 1/2 clinical trial seeks to evaluate the safety, pharmacokinetics and anti-tumor activity of "JIN-A02" in advanced NSCLC patients carrying EGFR mutations. This global phase 1/2 clinical trial seeks to evaluate the safety, pharmacokinetics and anti-tumor activity of "JIN-A02" in advanced NSCLC patients carrying EGFR mutations. 'JIN-A02' is a novel orally administered 4th Generation EGFR TKI, which is highly selective for and strongly inhibits NSCLC with C797S…

Santhera Completes Divestment of Raxone®/Idebenone Business to Chiesi Group

Ad hoc announcement pursuant to Art. 53 LRChiesi Group acquires entire idebenone business including Raxone inLeber's hereditary optic neuropathy (LHON)Chiesi Group assumes French reimbursement liability of EUR 25.3 million from SantheraSanthera retains contingent value forLHON in U .S . and/or other indications worldwideSanthera ceases all Raxone-related activities andintensifies commercial preparation for Duchenne muscular dystrophy...

Financière de Tubize - 2023 half-year financial report

Press release 29 July 2023FINANCIERE DE TUBIZE SAAllée de la Recherche 60, 1070 BrusselsContact: Eric Nys, day-to-day management,eric.nys@financiere-tubize.be 2023 half-year financial report Regulated information 29 July 2023 The board of directors of Financière de Tubize has issued the 2023 half-year financial report. This report is available on the websitewww.financiere-tubize.beProfit for first half of 2023: € 91.1 million at 30 June...

OKYO Pharma Announces Proposed Public Offering of Ordinary Shares

LONDON and NEW YORK, July28, 2023(GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announced that it intends to offer to sell its ordinary shares in an underwritten public offering. All of the ordinary shares are to be sold by the Company. The Company expects to grant...

Pixium Vision announces the implementation of a bridge financing with Bpifrance…

Pixium Vision announces the implementation of a bridge financing with Bpifrance and Sofinnova and a reverse stock spliton the basis of 1 new share for 50 existingsharesBridge financing: 3 million Euro convertible shareholders' loan from Bpifrance and Sofinnova to extend cash runway tothe end of November 2023Publication of half-year financial statements postponed to September 2023Reverse stock split: implementation of a reverse stock...

Grant of Performance Share Units and reporting of transactions in accordance…

Pursuant to Ambu A/S' (Ambu) Remuneration Policy, a total of 198,872 Performance Share Units (PSUs) related to Ambu's long-term incentive programme (LTIP) for 2022/23 have been granted on 28 July 2023. 55,956 of the PSUs have been granted to the Executive Management and 142,916 of the PSUs have been granted to other key employees.The LTIP covers the financial year 2022/23, and the final allocation of PSUs will be within the range of 0-200% of the initial grant, subject to the actual...

RNA Analysis Market worth $9.9 Billion | MarketsandMarkets

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=240344576 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=240344576 Browse in-depth TOC on "RNA Analysis Market"178 - Tables 46 - Figures 263 - Pages RNA Analysis Market Scope: The reagents/consumables segment accounted for the largest share of the product & service segment in the RNA analysis market in 2022. Based on product...

SK-II UNVEILS "THE SECRET KEY" FILMS

TOKYO, July 28, 2023 /PRNewswire/ -- Some secrets are meant to be shared, not kept. This World PITERA™ Month, global prestige skincare brand SK-II gives you the keys to unlock the untold stories of well-known PITERA™ lovers' transformational journey to Crystal Clear Skin* in its latest campaign, "THE SECRET KEY". TOKYO,July 28, 2023/PRNewswire/ -- Some secrets are meant to be shared, not kept. This World PITERA™ Month, global prestige skincare brand SK-II gives you the keys to unlock…

Press release: Online availability of Sanofi's half-year financial report for…

Online availability of Sanofi's half-year financial report for 2023Paris , July 28, 2023. Sanofi announces that its half-year financial report for the period ending June 30, 2023 is now available and has been filed with the French market regulator Autorité des marchés financiers (AMF) and submitted to the U.S. Securities and Exchange Commission (SEC) under form 6-K.This document may be found on the company's corporate website:www.sanofi.comand downloaded from the “Investors”...

Mendus raises approximately SEK 317 million through the directed issue to Flerie…

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES. PLEASE REFER TO “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE. On June 8, 2023, Mendus AB...

Biogen to Acquire Reata Pharmaceuticals

SKYCLARYS ®recently approved in US as the only treatment indicated for patients with Friedreich's ataxia Proposed acquisition represents meaningful step forward in Biogen's strategy for sustainable growth, adding a highly complementary innovative product in an area of high unmet medical needExpected to be significantly accretive to Biogen's Non-GAAP diluted EPS beginning in 2025Biogen to host investor conference call today at 9:00 a.m. ET. CAMBRIDGE, Mass. and PLANO, Texas, July...

OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal…

OKYO plans a 40-patient OK-101 open-label clinical trial with Dr Pedram Hamrah, Tufts Medical Center, as Principal Investigator, a leading expert in treating patients with NCPSecond clinical indication for OK-101 which is currently in 240 patient phase 2 clinical trial to treat dry eye disease, with top-line data anticipated by end of 2023NCP trial anticipated to start in Q4 2023LONDON and NEW YORK, July28, 2023(GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), an...

Altri Comunicati